Loading Events

« All Events

  • This event has passed.

Cycle 3: Alzheimer’s Drug Discovery Foundation

July 31, 2017

LOI DUE JULY 31, 2017
Preclinical Drug Discovery
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project.
Program to Accelerate Clinical Trials (PACT)
Seeks to fund biomarker-based, proof-of-concept pilot clinical trials, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials. Up to $1.5 million.
Biomarkers Development
Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer’s disease, related dementias, and cognitive aging. $150,000-$300,000/year, 1-2 years.
Prevention Beyond the Pipeline
The ADDF seeks to support prevention drug discovery not covered by most research funders or our current RFPs. Funding can range from $50,000-$100,000 for epidemiological analyses, $150,000-$600,000 for preclinical research, and up to $1.5 million for clinical trials.
Accelerating Drug Discovery for Frontotemporal Degeneration
Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration. Funding can range from $100,000-$150,000 per year, average one year duration.


July 31, 2017
Event Category: